Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma
Neoadjuvant PD-1 inhibitors combined with chemotherapy show promising potential for patients with locally advanced ESCC, inducing a robust immune response that correlates with clinical outcomes. The infiltration of myCAF emerges as a potential predictive biomarker for treatment response and disease progression, underscoring the need for further mechanistic exploration and validation in larger cohorts.
Authors
- Jiang Chang
- Yujie Zhang (ORCID: https://orcid.org/0000-0002-9109-3171)
- Li Zhang (ORCID: https://orcid.org/0000-0002-8433-2402)
- Wei Sun (ORCID: https://orcid.org/0009-0000-1934-4186)
- Yixin Cai
- Ni Zhang
- Jinjie Li (ORCID: https://orcid.org/0000-0002-4439-6276)
- Yueping Li (ORCID: https://orcid.org/0009-0005-7134-5502)
- Ruijie Zhang (ORCID: https://orcid.org/0000-0002-7293-9653)
- Qi Wang (ORCID: https://orcid.org/0009-0007-1839-7914)
- Siyou Deng
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1007/s00262-025-04099-9
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Science Foundation
- National Natural Science Foundation of China